Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:

About the Authors

С. Марцевич

Russian Federation

Н. Кутишенко

Russian Federation

С. Толпыгина

Russian Federation

Ю. Лукина

Russian Federation

А. Концевая

Russian Federation

А. Лишута

Russian Federation

Л. Иванова

Russian Federation

Л. Дроздова

Russian Federation

Е. Гофман

Russian Federation


1. Российский статистический ежегодник 2010. Москва 2010.

2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. Jan 29 2008;117(4):e25-146.

3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. Apr 15 1998;279(15):1200-1205.

4. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. Jan 22-29 1997;277(4):307-311.

5. WorldHealthOrganization. Requirements for adverse reaction reporting. . Geneva,Switzerland: 1975.

6. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf. Feb 1994;10(2):93-102.

7. Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. Jul 14 2007;370(9582):185-191.

8. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA : the journal of the American Medical Association. Dec 3 2008;300(21):2514-2526.

9. Saito Y, Morimoto T, Ogawa H, et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. Feb 2011;34(2):280-285.

10. Moore TJ, Vollmer WM, Appel LJ, et al. Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. Hypertension. Sep 1999;34(3):472-477.

11. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA : the journal of the American Medical Association. Mar 5 1997;277(9):739-745.

12. Celis H, Yodfat Y, Thijs L, et al. Antihypertensive therapy in older patients with isolated systolic hypertension: the Syst-Eur experience in general practice. The Syst-Eur Investigators. Fam Pract. Apr 1996;13(2):138-143.

13. Bulpitt CJ, Fletcher AE, Amery A, et al. The Hypertension in the Very Elderly Trial (HYVET). Journal of human hypertension. Aug 1994;8(8):631-632.

14. Dahlof B, Devereux R, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. American journal of hypertension. Jul 1997;10(7 Pt 1):705-713.

15. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. Sep 10-16 2005;366(9489):895-906.

16. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. American journal of hypertension. Sep 2004;17(9):793-801.

17. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA : the journal of the American Medical Association. May 21 2003;289(19):2560-2572.

18. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. Jun 2007; 25(6):1105-1187.

19. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. Mar 2009;122(3):290-300.

20. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. Jan 20 2007;369(9557):201-207.

21. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? American journal of hypertension. Jul 1996;9(7):695-699.

22. Kizer JR, Kimmel SE. Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards. Archives of internal medicine. May 14 2001;161(9):1145-1158.

23. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. European heart journal. Aug 2001;22(15):1343-1352.

24. Tenenbaum A, Grossman E, Fisman EZ, et al. Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. Journal of human hypertension. Jun 2001;15(6):373-379.

25. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer. May 1998;77(9):1508-1513.

26. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. Jul 2010;11(7):627-636.

27. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. Jan 2011;12(1):65-82.

28. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA : the journal of the American Medical Association. Aug 23-30 1995;274(8):620-625.

29. Oliver MF. Cholesterol, coronaries, clofibrate and death. N Engl J Med. Dec 14 1978;299(24):1360-1362.

30. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. Nov 16 1995;333(20):1301-1307.

31. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scot-land Coronary Prevention Study. N Engl J Med. Oct 11 2007;357(15):1477-1486.

32. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. May 27 1998;279(20):1615-1622.

33. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. Apr 5 2003;361(9364):1149-1158.

34. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. Aug 21-27 2004;364(9435):685-696.

35. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. Nov 20 2008;359(21):2195-2207.

36. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. Nov 27 2006;166(21): 2307-2313.

37. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

38. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. Nov 12 1987;317(20):1237-1245.

39. Forster T. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study]. Orv Hetil. Jul 22 2001;142(29):1588-1589.

40. Goldenberg I, Benderly M, Goldbourt U. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol. Jan 29 2008;51(4):459-465.

41. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. Nov 26 2005;366(9500):1849-1861.

42. Noto H, Kinoshita M. [VA-HIT Study [Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study]]. Nippon Rinsho. Mar 2001;59 Suppl 3:442-447.

43. Farmer JA. Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial). Curr Atheroscler Rep. Mar 2009;11(2):81-82.

44. Амлаев К. Р., Муравьева В. Н. , Чуркин А.А., Творогова Н.А. . Возрастная структура учтенного контингента, употребляющих психоактивные вещества в Российской Федерации. Профилактика и реабилитация в наркологии. 2002;1:8-11.

45. Александров А.А., Александрова В.Ю., Ваганов А.Д. , др. и. Изучение распространенности курения среди подростков — основа разработки мероприятий по профилактике сердечно-сосудистых заболеваний. Профилактика заболеваний и укрепление здоровья. 2003;1: 65-69.

46. Скворцова Е.С., Романова Е.В., Крошнин С. М., . Курение среди подростков-школьников в Подмосковье. Материалы конференции «Ситуация, связанная с курением табака в России. Пассивное курение. Лечение табачной зависимости». 2001:48- 52.

47. Левшин В.Ф., Слепченко Н. И. , Радкевич Н.В. Рандомизированное контролируемое исследование эффективности препарата Табекс при лечении табачной зависимости. Медицинский вестник. 2009;33:502-503.

48. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. May 2006;60(5):571-576.

49. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. Sep 2006;70(3):801-805.

50. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. Jan 2006;34(1):121-130.

51. Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. Jul 2007;28(7):316-325.

52. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. Jul 5 2006;296(1):64-71.

53. Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother. Feb 2007;7(2):121-127.

54. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. Aug 2008;63(8):717-724.

55. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. Jul 5 2006;296(1):47-55.

56. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. Jul 5 2006;296(1):56-63.

57. Obesity : guidance on the prevention, identification, assessment and mangement of overweight and obesity in adults and children : quick reference guide 1 : for local authorities, schools and early years providers, workplaces and the public. London: National Institute for Health and Clinical Excellence; 2006.

58. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. Apr 5 2005;142(7):525-531.

59. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003(4):CD004094.

60. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. Jan 2004;27(1):155-161.

61. Sibutramine (Meridia) withdrawn. Med Lett Drugs Ther. Nov 1 2010;52(1350):88.

62. Williams G. Withdrawal of sibutramine in Europe. BMJ. 2010;340:c824.

63. Lindstrom J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. Dec 2003;26(12):3230-3236.

64. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. Feb 2006;49(2):289-297.

65. Elmstahl S, Riboli E, Lindgarde F, Gullberg B, Saracci R. The Malmo Food Study: the relative validity of a modified diet history method and an extensive food frequency questionnaire for measuring food intake. Eur J Clin Nutr. Mar 1996;50(3):143-151.

66. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. Feb 7 2002;346(6):393-403.

67. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. Oct 1998;21(10):1720-1725.

68. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. Apr 1998;19(2):217-231.

69. McFarlane SI, Rundek T, Nicasio J, Deshmukh M, Sowers JR. The DREAM trial and the prospect of diabetes prevention. Curr Diab Rep. Jun 2006;6(3):205-206.

70. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. Apr 22 2010;362(16):1477-1490.

71. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. Jul 10 2010;376(9735):103-111.

72. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. Nov 10 2004;292(18): 2227-2236.

73. Шальнова С.А., Марцевич С.Ю., Деев А.Д., Лукина Ю.В., Оганов Р.Г. Первые результаты многоцентрового рандомизированного клинического исследования по применению препарата Акридилол в комбинированной терапии у больных артериальной гипертонией и ожирением или сахарным диабетом 2-го типа (АККОРД). Кардиология. 2008;8:28-33

74. Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. . Сравнение метаболических эффектов карведилола и метопролола у пациентов с артериальной гипертонией и избыточной массой тела/ожирением. Исследование КАМЕЛИЯ. Рациональная фармакотерапия в кардиологии. 2009;5:33-38.

75. Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Chin Med J (Engl). Sep 1995;108(9):710-717.

76. Neal B, Anderson C, Chalmers J, MacMahon S, Rodgers A. Blood pressure lowering in patients with cerebrovascular disease: results of the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) pilot phase. Clin Exp Pharmacol Physiol. May 1996;23(5):444-446.

77. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. Jun 2005;36(6):1218-1226.

78. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. Neurology. May 6 2008;70(19 Pt 2):1858-1866.

79. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. Jun 2006;27(11):1341-1381.

80. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. Sep 4-10 2004;364(9437):849-857.

81. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. Apr 13 2002;359(9314):1269-1275.

82. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet. Dec 12 1992;340(8833):1421-1425.

83. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med. May 15 1991;114(10): 835-839.

84. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CA-PRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329-1339.

85. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. Nov 19 1994;344(8934):1383-1389.

86. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. Jul 6 2002;360(9326):7-22.

87. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. Jan 15 2004;93(2):154-158.

88. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. Nov 16 2005;294(19):2437-2445.

89. Metelitsa VI, Martsevich S, Kozyreva MP, Slastnikova ID. Enhancement of the efficacy of isosorbide dinitrate by captopril in stable angina pectoris. Am J Cardiol. Feb 1 1992;69(4):291-296.

90. Texter M, Lees RS, Pitt B, Dinsmore RE, Uprichard AC. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc Drugs Ther. Apr 1993;7(2):273-282.

91. Lee RT. The PEACE study: limiting the role of angiotensin-converting enzyme inhibitors in stable coronary artery disease. Curr Atheroscler Rep. May 2005;7(3):211-212.

92. Kleinert S. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Lancet. Sep 4 1999;354(9181):841.

93. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. Sep 6 2003;362(9386):782-788.

94. Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation. Oct 6 2009;120(14):1380-1389.

95. Joyce D, Loebe M, Noon GP, et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol. Nov 2003;18(6):454-457.

96. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. Apr 2 1981;304(14):801-807.

97. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials. Eur Heart J. Jan 1992;13(1):28-32.

98. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. Nov 5 2005;366(9497):1622-1632.

99. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. May 5 2001;357(9266):1385-1390.

100. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. Sep 3 1992;327(10):669-677.

101. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. Oct 2 1993;342(8875):821-828.

102. The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group. Am J Cardiol. Apr 7 1994;73(10):44C-50C.

103. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nel-l'infarto Miocardico. Lancet. May 7 1994;343(8906):1115-1122.

104. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. Mar 18 1995;345(8951):669-685.

105. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. Sep 3 1992;327(10):678-684.

106. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. Mar 18 1995;345(8951):686-687.

107. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. Jan 12 1995;332(2):80-85.

108. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with An-giotensin II Antagonist Losartan. Lancet. Sep 7 2002;360(9335):752-760.

109. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. Nov 13 2003;349(20):1893-1906.

110. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. Dec 2008;29(23): 2909-2945.

111. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. Apr 3 2003;348(14):1309-1321.

112. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. Sep 2 1999;341(10):709-717.

113. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. Aug 13 1988;2(8607):349-360.

114. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. Jan 12 2002;324(7329):71-86.

115. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494-502.

116. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. Nov 5 2005;366(9497):1607-1621.

117. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. Feb 28 2009;373(9665):723-731.

118. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. Jan 23 2010;375(9711):283-293.

119. Stone GW. Ticagrelor in ACS: redefining a new standard of care? Lancet. Jan 23 2010;375(9711): 263-265.

120. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. Dec 14 2010;122(24):2619-2633.

121. Moukarbel GV, Signorovitch JE, Pfeffer MA, et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J. Sep 2009;30(18):2226-2232.

122. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. Oct 28 2008;118(18): 1894-1909.

123. Kitchingman GK, Prichard PJ, Daneshmend TK, Walt RP, Hawkey CJ. Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine. Br J Clin Pharmacol. Nov 1989;28(5): 581-585.

124. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin «resistance» and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. Jan 26 2008;336(7637):195-198.

125. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. May 13 2008;51(19):1829-1843.

126. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. Apr 4 2001;285(13):1711-1718.

127. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. May 20 2008;51(20): 1925-1934.

128. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. Oct 16 2010;376(9749):1312-1319.

129. Holmes DR, Jr., Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA «boxed warning»: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. Jul 20 2010;56(4):321-341.

130. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. Oct 28 2010;363(18):1704-1714.

131. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. Oct 9 2010;376(9748):1233-1243.

132. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. Nov 11 2010;363(20):1909-1917.

133. Simon T, Steg PG, Gilard M, et al. Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation. Feb 8 2011;123(5):474-482.

134. Ferreiro JL, Ueno M, Capodanno D, et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv. Oct 2010;3(5):436-441.

135. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. Jul 2007;28(13):1598-1660.

136. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. Oct 3 1996;335(14):1001-1009.

137. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. Nov 5 1998;339(19):1349-1357.

138. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. Sep 15 2004;292(11):1307-1316.

139. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. Apr 8 2004;350(15):1495-1504.

140. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. Aug 31 2004;110(9):e82-292.

141. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. May 2004;64(2):137-151.

142. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. Nov 29 2001;345(22):1583-1592.

143. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. Dec 7 2004;110(23):3512-3517.

144. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. Dec 18 2002;40(12):2125-2134.

145. Farmer JA. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial). Curr Atheroscler Rep. Mar 2009;11(2):82-83.

146. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of

147. Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. Nov 2008;156(5):826-832.

148. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (IV пересмотр). . Кардиоваскулярная терапия и профилактика. 2009;8(6):58.

149. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. Dec 19 1990;264(23):3013-3017.

150. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression of coronary disease. Observations from the FATS Trial. Familial Atherosclerosis Treatment Study. Ann N Y Acad Sci. Jan 17 1995;748:407-417; discussion 417-408.

151. Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res. Dec 2008;49(12):2641-2647.

152. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. Apr 2005;41(4):690-695.

153. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. Apr 17 2006;97(8A):52C-60C.

154. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. Apr 17 2006;97(8A):77C-81C.

155. Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int. Mar 2009;29 Suppl 2:3-12.

156. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. May 2004;174(1):193-196.

157. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. Feb 15 2005;95(4):462-468.

158. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandina vian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. Jun 4 1987;316(23):1429-1435.

159. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. Aug 1 1991;325(5):293-302.

160. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. Aug 10 2006;355(6):549-559.

161. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. Jun 30 1979;1(8131):1374-1376.

162. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. Oct 1994;90(4):1765-1773.

163. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. Jan 2 1999;353(9146): 9-13.

164. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. Mar 8 2000;283(10):1295-1302.

165. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. May 31 2001;344(22):1651-1658.

166. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. Feb 2005;26(3):215-225.

167. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. Jul 5 2003;362(9377):7-13.

168. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. Oct 2008;29(19):2388-2442.

169. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. Dec 2001;38(7):2101-2113.

170. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. Jan 6 2011;364(1):11-21.

171. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. May 6 2000;355(9215):1582-1587.

172. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. Dec 6 2001;345(23):1667-1675.

173. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. Sep 6 2003;362(9386):772-776.

174. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. Sep 6 2003;362(9386):767-771.

175. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. Feb 20 1997;336(8):525-533.

176. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. Sep 29 2001;358(9287):1033-1041.

177. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. Mar 23 2002;324(7339):699-702.

178. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. Nov 2003;34(11):2741-2748.

179. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. Nov 1996;143(1-2):1-13.

180. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. May 20 2006;367(9523):1665-1673.

181. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. Jun 19 2007;146(12):857-867.

182. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. Sep 17 2009;361(12):1139-1151.

183. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. Feb 12 2009;360(7):668-678.

184. Adherence to long-term therapies : evidence for action. Geneva: WHO; 2003.

185. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. Sep 2005;21(9):1453-1460.

186. Hosie J, Wiklund I. Managing hypertension in general practice: can we do better? J Hum Hypertens. Jul 1995;9 Suppl 2:S15-18.

187. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. Aug 4 2005;353(5):487-497.

188. Sung JC, Nichol MB, Venturini F, Bailey KL, McCombs JS, Cody M. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. Oct 1998;4(10):1421-1430.

189. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. Jan 1986;24(1):67-74.

190. Paschal AM, Hawley SR, St Romain T, Ablah E. Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions. Epilepsia. Jul 2008;49(7):1115-1122.

191. Незнанов Н.Г., Вид В.Д. Проблема комплаенса в клинической психиатрии. Психиатрия и психофармакотерапия. 2004;6(4):159-162.

192. Izzo JL, Black HR, Goodfriend TL. Hypertension primer : the essentials of high blood pressure. 3rd ed. ed. Philadelphia: Lippincott Williams & Wilkins; 2003:390-392.

193. Joyce CR, Caple G, Mason M, Reynolds E, Mathews JA. Quantitative study of doctor-patient communication. Q J Med. Apr 1969;38(150):183-194.

194. Makaryus AN, Friedman EA. Patients' understanding of their treatment plans and diagnosis at discharge. Mayo Clin Proc. Aug 2005;80(8):991-994.

195. Neutel JM, Smith DH. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens (Greenwich). Mar-Apr 2003;5(2):127-132.

196. Плавинский С.Л., . Мероприятия по усилению приверженности терапии. 2007:48.

197. Piette JD, Heisler M, Krein S, Kerr EA. The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med. Aug 8-22 2005;165(15):1749-1755.

198. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Levin R, Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hyper-tens. Jul 1997;10(7 Pt 1):697-704.

199. Lee JY, Kusek JW, Greene PG, et al. Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens. Aug 1996;9(8):719-725.

200. Wrigley S, Jackson H, Judd F, Komiti A. Role of stigma and attitudes toward help-seeking from a general practitioner for mental health problems in a rural town. Aust N Z J Psychiatry. Jun 2005;39(6):514-521.

201. Воробьев П.А., ed Клинико-экономический анализ. Москва: «Ньюдиамед»; 2008.

202. ОСТ «Клинико-экономические исследования. Общие положения. 91500.14.0001-2002».

Views: 535

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)